Terms: = Uterine cancer AND FUBP1, FBP, 8880, ENSG00000162613, FUBP
10 results:
1. The expression and clinical value of LRP11, fubp1 and TET1 in cervical cancer.
Zhao X; Li S; Wen J; Li Y
Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):80-84. PubMed ID: 37715422
[TBL] [Abstract] [Full Text] [Related]
2. A mass spectrometry-based approach for the identification of Kpnβ1 binding partners in cancer cells.
Okpara MO; Hermann C; van der Watt PJ; Garnett S; Blackburn JM; Leaner VD
Sci Rep; 2022 Nov; 12(1):20171. PubMed ID: 36418423
[TBL] [Abstract] [Full Text] [Related]
3. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S; Kojima Y; Yoshida H; Takamizawa S; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Saito A; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Ohe Y; Yonemori K
J Gynecol Oncol; 2022 Nov; 33(6):e82. PubMed ID: 36245230
[TBL] [Abstract] [Full Text] [Related]
4. LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with fubp1 to activate c-MYC.
Qian X; Yang J; Qiu Q; Li X; Jiang C; Li J; Dong L; Ying K; Lu B; Chen E; Liu P; Lu Y
J Hematol Oncol; 2021 Jul; 14(1):112. PubMed ID: 34274028
[TBL] [Abstract] [Full Text] [Related]
5. TNPO1-Mediated Nuclear Import of fubp1 Contributes to Tumor Immune Evasion by Increasing NRP1 Expression in Cervical cancer.
Yang B; Chen J; Teng Y
J Immunol Res; 2021; 2021():9994004. PubMed ID: 33987449
[TBL] [Abstract] [Full Text] [Related]
6. Overexpression of fubp1 is associated with human cervical carcinoma development and prognosis.
Ma C; Huang Z; Wu Z; Di C; Lin X; Huang M; Hong H; Yin H
Life Sci; 2021 Mar; 269():119098. PubMed ID: 33476628
[TBL] [Abstract] [Full Text] [Related]
7. NORAD orchestrates endometrial cancer progression by sequestering fubp1 nuclear localization to promote cell apoptosis.
Han T; Wu Y; Hu X; Chen Y; Jia W; He Q; Bian Y; Wang M; Guo X; Kang J; Wan X
Cell Death Dis; 2020 Jun; 11(6):473. PubMed ID: 32555178
[TBL] [Abstract] [Full Text] [Related]
8. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
[TBL] [Abstract] [Full Text] [Related]
9. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO; Byrd K; Vreeland TJ; Hale DF; Herbert GS; Greene JM; Schneble EJ; Berry JS; Trappey AF; Clifton GT; Hardin MO; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwell GL; Peoples GE
Oncotarget; 2017 Feb; 8(9):15912-15923. PubMed ID: 27852036
[TBL] [Abstract] [Full Text] [Related]
10. Activation of human insulin-like growth factor binding protein-1 gene promoter by a distal regulatory sequence in a human endometrial adenocarcinoma cell line.
Gao J; Mazella J; Tseng L
Mol Endocrinol; 1995 Oct; 9(10):1405-12. PubMed ID: 8544848
[TBL] [Abstract] [Full Text] [Related]
